ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $78,920 | +15.2% | 842,801 | +9.8% | 1.23% | +25.1% |
Q2 2023 | $68,493 | -25.0% | 767,427 | -9.9% | 0.98% | -26.4% |
Q1 2023 | $91,360 | -5.5% | 852,080 | +7.7% | 1.34% | -2.9% |
Q4 2022 | $96,635 | -99.9% | 791,245 | +23.7% | 1.38% | +49.6% |
Q3 2022 | $66,053,000 | +58.0% | 639,675 | +42.3% | 0.92% | +57.6% |
Q2 2022 | $41,799,000 | -28.8% | 449,650 | -10.2% | 0.58% | -11.5% |
Q1 2022 | $58,733,000 | -19.8% | 500,450 | -8.1% | 0.66% | +1.5% |
Q4 2021 | $73,278,000 | -21.3% | 544,700 | -6.8% | 0.65% | -20.2% |
Q3 2021 | $93,148,000 | +94.9% | 584,400 | +60.9% | 0.81% | +107.9% |
Q2 2021 | $47,792,000 | -20.5% | 363,300 | -22.1% | 0.39% | -24.1% |
Q1 2021 | $60,097,000 | -16.8% | 466,300 | +7.6% | 0.52% | -12.3% |
Q4 2020 | $72,249,000 | +8.4% | 433,200 | +0.3% | 0.59% | -5.9% |
Q3 2020 | $66,645,000 | +96.3% | 431,860 | +88.1% | 0.62% | +92.6% |
Q2 2020 | $33,952,000 | – | 229,560 | – | 0.32% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |